3 May 2023

A year of significant advances to improve rare disease diagnosis in children

January 21, 2016

CAMBRIDGE, Massachusetts; January 21, 2016 – 2015 was a year of advances for Claritas Genomics continuing the company’s mission to advance precision care for children. The company secured $15 million for its Series B, launched new diagnostic gene tests, announced a partnership with the world’s largest rare disease patient advocacy organization, sequenced 19,600 research exomes, announced its Scientific Advisory Board and became one of only eight clinical laboratories in the US to be awarded the International Standardization Organization’s (ISO) 15189 accreditation by the American Association for Laboratory Accreditation (A2LA).  In 2015, Claritas:

  • Secured $15 million in capital for its Series B Round
  • Launched the Pediatric Neurology Region of Interest (ROI) diagnostic test focusing on six different neurology indications. Results of this test in the first patient to receive it were covered in Bloomberg Businessweek and Bloomberg News
  • Announced partnership with Genetic Alliance to enable patients and families in clinical care to participate in pediatric rare disease research
  • Completed and delivered 19,600 research exomes (the protein-coding part of the genome) and 55 whole genome sequences to the Veterans Administration, fulfilling its Base year Contract for the VA’s One Million Veterans Program and initiated Year One Contract
  • Launched the Claritas Clinical Exome Next Generation Sequencing (NGS) and Array offerings, the first clinical exome test that gives healthcare providers multiple options to find answers for patients quickly and cost effectively  
  • Launched the Claritas Genomics Scientific Advisory Board
  • Was awarded ISO 15189 accreditation for molecular diagnostic testing by the A2LA

About Claritas Genomics
Claritas Genomics serves children affected with complex genetic disorders by providing timely and accurate results, resolving families’ long search for answers. By combining clinical expertise of the world’s best pediatric specialists with innovative platform solutions, Claritas is working to improve patient care and enable new discoveries.

For more information about Claritas Genomics, visit www.claritasgenomics.com

Contact:
Betsy Stevenson
Director of Corporate Communications
[email protected]
Tel: (860) 984-1424